O-Z-DL-Milchsaeure | 95011-47-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-Z-DL-Milchsaeure
• 英文别名: 2-Phenylmethoxycarbonyloxypropanoic acid
• CAS: 95011-47-5
• 化学式: C₁₁H₁₂O₅
• 分子量: 224.213
• InChiKey: XAXYOIHOFLJETA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  O-Z-DL-Milchsaeure 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 Z-Lactyl-N-methyl-DL-alanin-α-hydroxy-isovaleriansaeure-cyanmethylester
  参考文献：
  名称：

  Losse,G.; Bachmann,G., Chemische Berichte, 1964, vol. 97, p. 2671 - 2680

  摘要：

  DOI：
• 作为产物：
  描述：

  乳酸 、 氯甲酸苄酯 在 三乙胺 作用下， 以 氯仿 为溶剂， 生成 O-Z-DL-Milchsaeure
  参考文献：
  名称：

  Losse,G.; Bachmann,G., Chemische Berichte, 1964, vol. 97, p. 2671 - 2680

  摘要：

  DOI：

文献信息

• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• Methods for the synthesis of <scp>L</scp>-lactyl-<scp>L</scp>-valine-1-¹⁴C
  作者：G. P. Slater、H. Spencer

  DOI：10.1139/v68-114

  日期：1968.3.1

  The preparation of L-lactyl-L-valine from L-lactic acid and L-valine, by methods used for the synthesis of peptides, was investigated. Initial experiments with O-benzoyl-DL-lactic acid and DL-valine benzyl ester unexpectedly gave N-benzoyl-DL-valine benzyl ester. However, coupling between O-benzyloxycarbonyl-DL-lactic acid and either DL-valine, or DL-valine benzyl ester, occurred in good yield. A simpler method, which was reported to give a 39% yield of L-lactyl-L-valine, gave only 10% of product but was modified to give L-lactyl-L-valine-1-¹⁴C in 90% yield.

  从L-乳酰基-L-缬氨酸通过用于合成肽的方法从L-乳酸和L-缬氨酸制备，进行了研究。最初使用O-苯甲酰-DL-乳酸和DL-缬氨酸苄酯进行的实验意外地产生了N-苯甲酰-DL-缬氨酸苄酯。然而，O-苄氧羰基-DL-乳酸与DL-缬氨酸或DL-缬氨酸苄酯之间的偶联反应收率较高。一种更简单的方法据报道可得到39%的L-乳酰基-L-缬氨酸产率，但实际只有10%的产物，但经改进后可得到90%产率的L-乳酰基-L-缬氨酸-1-14C。
• Benzoxepin pi3k inhibitor compounds and methods of use
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2784078A1

  公开（公告）日：2014-10-01

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  式 I 的苯氧西泮化合物，包括其立体异构体、几何异构体、同分异构体、溶 剂、代谢物和药学上可接受的盐，其中：Z1 是 CR1 或 N；Z2 是 CR2 或 N；Z3 是 CR3 或 N；Z4 是 CR4 或 N；以及 其中：(i) X1 是 N，X2 是 S；(ii) X1 是 S，X2 是 N；(iii) X1 是 CR7，X2 是 S；(iv) X1 是 S，X2 是 CR7；(v) X1 是 NR8，X2 是 N，(vi) X1 是 N，X2 是 NR8，(vii) X1 是 CR7，X2 是 O，(viii) X1 是 O，X2 是 CR7，(ix) X1 是 CR7，X2 是 C(R7)2，(x) X1 是 C(R7)2，X2 是 CR7；(xi) X1 是 N，X2 是 O，或 (xii) X1 是 O，X2 是 N，这些化合物可用于抑制脂质激酶，包括 p110 alpha 和 PI3K 的其他同工型，以及治疗由脂质激酶介导的疾病，如癌症。公开了使用式 I 化合物体外、原位和体内诊断、预防或治疗哺乳动物细胞中的此类疾病或相关病理状况的方法。
• US8263633B2
  申请人：——

  公开号：US8263633B2

  公开（公告）日：2012-09-11
• US8673952B2
  申请人：——

  公开号：US8673952B2

  公开（公告）日：2014-03-18